Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Centessa Pharmaceuticals ( (CNTA) ) has issued an update.
On November 24, 2025, Centessa Pharmaceuticals amended its Sales Agreement with Leerink Partners LLC, allowing the company to issue and sell up to $250 million of its American Depositary Shares through ‘at the market offerings.’ This strategic move, facilitated by Leerink as the sales agent, aims to provide Centessa with flexibility in raising capital for working capital, capital expenditures, and general corporate purposes. The agreement includes customary representations, warranties, and covenants, and does not obligate the company to sell any shares, nor does it specify a minimum offering amount. The impact of this agreement could enhance Centessa’s financial resources, potentially strengthening its market position and operational capabilities.
The most recent analyst rating on (CNTA) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Centessa Pharmaceuticals stock, see the CNTA Stock Forecast page.
Spark’s Take on CNTA Stock
According to Spark, TipRanks’ AI Analyst, CNTA is a Underperform.
Centessa Pharmaceuticals has a low overall stock score due to significant financial challenges, including ongoing losses, negative cash flow, and a bearish technical outlook. The lack of profitability reflected in the negative P/E ratio further contributes to the low score. Investors should be cautious, considering the company’s need for additional funding to sustain operations in the capital-intensive biotechnology industry.
To see Spark’s full report on CNTA stock, click here.
More about Centessa Pharmaceuticals
Centessa Pharmaceuticals plc operates in the pharmaceutical industry, focusing on the development and commercialization of innovative medicines. The company primarily engages in the creation of novel therapeutic products aimed at addressing unmet medical needs.
Average Trading Volume: 1,536,670
Technical Sentiment Signal: Buy
Current Market Cap: $3.76B
See more insights into CNTA stock on TipRanks’ Stock Analysis page.